These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 3527821)
21. New hepatitis B vaccines. Zuckerman AJ Br Med J (Clin Res Ed); 1985 Feb; 290(6467):492-6. PubMed ID: 3918647 [No Abstract] [Full Text] [Related]
22. Subunit, recombinant and synthetic hepatitis B vaccines. Zuckerman AJ Scand J Gastroenterol Suppl; 1985; 117():27-38. PubMed ID: 3912963 [TBL] [Abstract][Full Text] [Related]
23. [Infection by hepatitis B virus and its prevention]. Kashiwagi S Rinsho Byori; 1987 Jan; 35(1):9-16. PubMed ID: 3560486 [No Abstract] [Full Text] [Related]
26. Vaccination against hepatitis B--the current situation. Jilg W; Deinhardt F Infection; 1986; 14(3):100-1. PubMed ID: 2942487 [No Abstract] [Full Text] [Related]
27. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. André FE Am J Med; 1989 Sep; 87(3A):14S-20S. PubMed ID: 2528292 [TBL] [Abstract][Full Text] [Related]
28. A low rate of hepatitis B virus vaccine breakthrough infections in Mongolia. Ijaz S; Khulan J; Bissett SL; Ferns RB; Nymadawa P; Tedder RS J Med Virol; 2006 Dec; 78(12):1554-9. PubMed ID: 17063521 [TBL] [Abstract][Full Text] [Related]
29. Prospects for second and third generation hepatitis B vaccines. Purcell RH; Gerin JL Hepatology; 1985; 5(1):159-63. PubMed ID: 3967858 [No Abstract] [Full Text] [Related]
30. Hepatitis B vaccine. Capiau C Dev Biol Stand; 1998; 96():127-9. PubMed ID: 9890526 [No Abstract] [Full Text] [Related]
31. [Current status of the problem of viral hepatitis B prophylaxis]. Golosova TV; Vlasikhina EM Probl Gematol Pereliv Krovi; 1980 Sep; 25(9):49-55. PubMed ID: 6999496 [No Abstract] [Full Text] [Related]
32. Infections by hepatitis B surface antigen gene mutants in Europe and North America. Tabor E J Med Virol; 2006; 78 Suppl 1():S43-7. PubMed ID: 16622882 [TBL] [Abstract][Full Text] [Related]
33. Evaluation on expression of the recombinant S gene of human hepatitis B virus in vitro and in vivo. Yang RY; Zeng QP; Fu LC; Chen ZT Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):259-64. PubMed ID: 14599980 [TBL] [Abstract][Full Text] [Related]
34. [Hepatitis B virus. Application of recombinant DNA technics to the development of hepatitis B vaccines and its diagnosis]. Hamada F Rinsho Byori; 1988 May; 36(5):548-52. PubMed ID: 2971829 [No Abstract] [Full Text] [Related]
35. Recombinant yeast-derived hepatitis B vaccine: the prototype for biotechnologically derived old vaccines. Ellis RW Bioprocess Technol; 1991; 13():355-69. PubMed ID: 1368626 [No Abstract] [Full Text] [Related]
37. Newer directions in vaccine development and utilization. Hilleman MR J Infect Dis; 1985 Mar; 151(3):407-19. PubMed ID: 2982958 [TBL] [Abstract][Full Text] [Related]
38. [Screening for hepatitis B]. Krogsgaard K Ugeskr Laeger; 2002 Jan; 164(2):159-62. PubMed ID: 11831078 [No Abstract] [Full Text] [Related]
39. A novel hepatitis B virus variant S 129 (Gln-->Leu): lack of correlation between antigenicity and immunogenicity. Wu L; He JW; Yao X; Li HM; Wen YM J Med Virol; 1999 Dec; 59(4):424-30. PubMed ID: 10534722 [TBL] [Abstract][Full Text] [Related]
40. [Possibilities of eradicating the persistent HBsAg carrier state]. Farber NA; Ambrozaĭtis AK; Kelli EI; Vygodskiĭ VS; Savitskiĭ GI Ter Arkh; 1984; 56(11):99-103. PubMed ID: 6523400 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]